Table 1 Demographic clinical and imaging data from the whole systemic sclerosis patient population
Demographic, clinical and imaging data in SSc PTs | Mean ± SD OR number-percentage |
|---|---|
Age (years, mean ± SD) | 63 ± 13 |
Sex (females/males) | 50/5 |
RP duration (years, mean ± SD) | 5.8 ± 10 |
SSc duration (years, mean ± SD) | 8.4 ± 6 |
SSc form = LcSSc/dcSSc (n = %) | 36 = 65.5% / 19 = 34.5% |
ANA (n = %) | 55 = 100% |
ACA (n = %) | 20 = 36.4% |
Anti-Scl-70 Ab (n = %) | 23 = 41.8% |
ILD at CT scan (n = %) | 37 = 67.3% |
Ground glass opacities, lower lobes (n = %) | 13 = 23.6% |
Ground glass opacities, upper lobes (n = %) | 8 = 14.5% |
Ground glass opacities, upper and lower lobes (n = %) | 8 = 14.5% |
Peripheral septal thickening (n = %) | 31 = 56.4% |
Apical fibrotic changes (n = %) | 20 = 36.4% |
Diffused fibrotic changes (n = %) | 15 = 27.3% |
Enlarged mediastinal nodes (n = %) | 16 = 29.1% |
Traction bronchiectasis and bronchiolectasis (n = %) | 16 = 29.1% |
FVC% (mean ± SD) | 104 ± 24 |
DLCO/VA% (mean ± SD) | 71.5 ± 20 |
sPAP mmHg (mean ± SD) | 34 ± 7 |
Pro-BNP (pg/ml, mean ± SD) | 1423 ± 5119 |
On immunosuppressive therapy (n = %) | 32 = 56.1% |
On glucocorticoids (n = %) | 9 = 16.4% |
On ERAs (n = %) | 16 = 28.1% |